Table 5.
GI-NET results: [177Lu]Lu-DOTA-TATE versus SoC, [177Lu]Lu-DOTA-TATE versus everolimus.
| Treatment modalities | Costs | QALYs | Incremental costs | Incremental QALYs | ICER (cost/QALY) | P (cost-effective) at WTP £30,000 |
|---|---|---|---|---|---|---|
| SoC | £67,454 | 2.94 | ||||
| [177Lu]Lu-DOTA-TATE | £100,073 | 4.17 | (€34,040) | 1.23 | £26,528 (€27,672) | 77% |
| Everolimus | £74,687 | 3.1 | ||||
| [177Lu]Lu-DOTA-TATE | £100,584 | 4.17 | (€27,015) | 1.07 | £24,145 (€25,186) | 88% |
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract; P-NETs, neuroendocrine tumours located in the pancreas; QALYs, quality-adjusted life-years.
P stands for probability, SoC for standard of care and WTP for Willingness to Pay. In brackets the ICER values are provided for the costs in euros based on Purchasing Power Parity rates.